PS
Therapeutic Areas
Imugene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| azer-cel (azercabtagene zapreleucel) | CD19+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1b |
| onCARlytics (CF33-CD19) | Solid Tumors | Phase 1 |
| VAXINIA (CF33-hNIS) | Advanced Solid Tumors | Phase 1 |
| CHECKvacc | Solid Tumors | Phase 1 |
| HER-Vaxx | HER2+ Gastric/Breast Cancer | Phase 2/3 |
| PD1-Vaxx | Non-Small Cell Lung Cancer (NSCLC) & other solid tumors | Phase 1 |
| CLDN18.2 Program | CLDN18.2+ Gastrointestinal Cancers | Phase 1 |
Leadership Team at Imugene
LC
Leslie Chong
CEO & Managing Director
PH
Paul Hopper
Executive Chairman
UM
Ursula McCurry
Chief Clinical Operations Officer
JB
John Byon
Chief Medical Officer
DK
Darren Keamy
Chief Financial Officer and Company Secretary
JD
Jakob Dupont
Non-Executive Director
KD
Kim Drapkin
Non-Executive Director
LR
Lesley Russell
Non-Executive Director
YF
Yuman Fong
Scientific Advisory Board Chair
PS
Prasad S. Adusumilli
Scientific Advisory Board Member